08:54 AM EDT, 07/30/2025 (MT Newswires) -- LENZ Therapeutics ( LENZ ) reported a Q2 net loss Wednesday of $0.53 per diluted share, compared with a loss of $0.40 a year earlier.

Analysts polled by FactSet expected a loss of $0.61.

Revenue for the quarter ended June 30 was $5 million, compared with no revenue a year earlier.

Analysts surveyed by FactSet expected $700,000.

As of June 30, the company said it had $209.6 million in cash, cash equivalents and marketable securities.

The company's shares were up over 6% in recent premarket activity.